Clinical Research Directory
Browse clinical research sites, groups, and studies.
China Lung Cancer Screening (CLUS) Study Version 3.0
Sponsor: Shanghai Chest Hospital
Summary
CLUS version 1.0, had proven that LDCT led to a 74.1% increase in detecting early-stage lung cancer compare to usual care (NCT02898441). CLUS version 2.0 evaluated the efficacy of new techniques (AI, AFI and MTB) in fostering the implementation of lung cancer screening (NCT03975504). The present multi-center study is performed to evaluate the effectiveness of different lung cancer screening strategy and validate our previous findings. 100,000 high-risk subjects (age 45-75) were recruited to take LDCT screening (Baseline + 2 biennial repeated LDCT screening). Follow-up for lung cancer incidence, lung cancer mortality and overall mortality was performed. Blood samples were stored in a Biobank. Management of positive screening test was carried out by a pre-specified protocol.
Official title: Lung Cancer Screening With Low-dose CT in China (CLUS Study) Version 3.0
Key Details
Gender
All
Age Range
45 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100000
Start Date
2022-01-01
Completion Date
2026-12-31
Last Updated
2022-08-09
Healthy Volunteers
Yes
Conditions
Interventions
Whole-process management software
Enrolled participants will managed by a pre-designed software. The software would provide helpful assistance, such as lung cancer education, decision-making, assisting in making and attending LCS LDCT appointments, arranging follow-up when needed, tobacco cessation support for smokers, treatment assistance if diagnosed as lung cancer.
LDCT detection
LDCT were performed in both arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
Locations (1)
Shanghai Chest hospital
Shanghai, Shanghai Municipality, China